Primary Cells Market

Primary Cells Market Size, Share & Trends by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Global Forecast to 2028

Report Code: BT 6489 Jul, 2023, by marketsandmarkets.com

Primary Cells Market Size, Share & Trends

The size of global primary cells market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.8 billion by 2028, growing at a CAGR of 10.5% from 2023 to 2028. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The growth of this market can be attributed to factors such as the is the growing advantages of primary human cells over cell lines, rising growth in pharmaceutical & biotechnology industries, increasing demand for monoclonal antibodies, Government investments for cell-based research, and increasing cancer research.

Primary Cells Market Trends

Primary Cells Market

To know about the assumptions considered for the study, Request for Free Sample Report

Primary Cells Market

Primary Cells Market Dynamics

DRIVER: Advantages of primary human cells over cell lines

Primary human cells have a wide range of advantages over in vitro cell lines; they provide reliable tissue-specific responses in a biologically relevant microenvironment. Drug responses in cell lines may not provide false responses in a cellular context. Moreover, primary human cells are cost-effective and help in reducing the expenditure on animal models required for in vivo studies. Pre-screened primary cells help in representing signaling in vivo very closely. Owing to this, pharmaceutical and biotechnology companies, as well as CROs, are increasingly shifting to primary human cells for their lead identification and optimization processes in drug discovery. Some of the key advantages of primary human cells include physiological relevance, genetic diversity, and tumor microenvironment representation, among others.

The conventional methods of toxicity and drug safety assessment involve animal testing, which is expensive, time-consuming, and low throughput. Thus, primary human cells present a preferable alternative for biochemical assays and animals because of their physiological relevance; inherent virtues; and ability to provide efficient, cost-effective, and accelerated drug discovery solutions. The use of primary cultures also tackles many ethical objections raised against animal experiments and allows for experimentation on human tissues, which is otherwise limited to in vitro studies. These advantages of human and animal primary cells are driving their adoption among end users and thereby fueling market growth.

RESTRAINT: Concerns regarding primary cell culture contamination

Contamination is a significant concern in primary cell cultures, as it can negatively impact experimental results, introduce variability, and compromise the reliability of research findings. Some of the main concerns regarding primary cell culture contamination include bacterial and fungal contamination, viral contamination, cross-contamination, and mycoplasma contamination. To minimize the risk of contamination, it is essential to follow good aseptic techniques and implement appropriate quality control measures. Implementing strict aseptic practices, performing regular monitoring, and testing, and using authenticated cells can minimize the risk of contamination in primary cell cultures, ensuring more reliable and reproducible experimental outcomes.

OPPORTUNITY: Advancing biomedical research using primary cells in 3D cultures

The use of primary cells in 3D cultures has advanced biomedical research by providing a more physiologically relevant model that better mimics the complexity and architecture of human tissues. Primary cells in 3D cultures have significantly advanced biomedical research by providing more physiologically relevant models for studying diseases, drug discovery, toxicity assessment, and personalized medicine. These models have the potential to bridge the gap between traditional cell culture and in vivo studies, leading to more accurate predictions and improved translation of research findings to clinical applications. Hence, the increasing use of primary cells with 3D cultures in various R&D activities is expected to influence the demand for primary cells in the coming years. This is expected to provide a wide range of growth opportunities for players in the market.

CHALLENGE: Sourcing and availability of primary cells

Obtaining high-quality primary cells can be a challenge due to the limited availability of specific tissue types and donor variability. Sourcing primary cells from diverse patient populations and obtaining consent for tissue donation can be logistically challenging. Additionally, the availability of certain primary cell types may be limited, making it difficult to meet the demand for specific research needs. Sourcing and availability of primary cells can be a challenge due to several factors, such as tissue acquisition, donor variability, tissue preservation, and transport, and the limited availability of specific cell types. Addressing these challenges requires collaborations between researchers, tissue banks, and regulatory bodies to ensure a streamlined process for tissue acquisition, storage, and distribution. Efforts to expand tissue repositories, establish partnerships with healthcare institutions, and promote tissue donation can help enhance the availability of primary cells. Additionally, advances in techniques for cryopreservation, tissue storage, and transport can improve the accessibility and quality of primary cells, overcoming some of the challenges associated with sourcing and availability.

Primary Cells Market Ecosystem

In 2022, by origin, human primary cells segment dominated the primary cells industry.

On the basis of origin, the primary cells market is divided into animal and human primary cells. In 2022, the human primary cells segment accounted for the largest share of the market. Factors responsible for the growth of the segment include the extensive use of human primary cells for studying human cancerous cell models, as well as in toxicology studies. The driving factors for the human market also include the demand for accurate disease models, advancements in research and drug discovery, the rise of regenerative medicine, safety testing requirements, the increasing burden of chronic diseases, technological innovations, ethical considerations, and collaborative initiatives within the scientific community.

Hematopoietic cells segment accounted for the largest share in the primary cells industry, by type in 2022.

On the basis of type, the primary cells market is divided into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2022, the hematopoietic cells segment accounted for the largest market share. Factors such as use of Hematopoietic cell transplants and to develop novel cancer therapies to treat blood cancers and other disorders of the immune system are responsible for the segment growth. Hepatocytes, due to their increasing demand in toxicological and pharmacological studies, are expected to witness the highest growth in the market.

In 2022, the pharmaceutical & biotechnology companies, and CROs segment accounted for the largest share of the global primary cells industry, by end user.

On the basis of end users, the primary cells market is segmented into pharmaceutical & biotechnology companies, and CROs, academic & research institutes, and other end users. In 2022, pharmaceutical & biotechnology companies and CROs accounted for the largest share of the market, mainly due to the high adoption of primary cells in cell-based experiments and cancer research in pharmaceutical & biotechnology companies and CROs, as well as the increasing number of R&D facilities globally.

In 2022, North America is the largest region for primary cells industry.

The global primary cells market is divided in four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America accounted for the largest share of the market, followed by Europe. Due to established clusters in North America and Europe, these regions are the preferred locations for drug discovery. Asia Pacific is expected to register the highest growth during the forecast period due to an increase in populations and a rise in the burden of diseases.

Primary Cells Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the primary cells market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), and Corning Incorporated (US).

Scope of the Primary Cells Industry

Report Metric

Details

Market Revenue Size in 2023

$1.7 billion

Projected Revenue Size by 2028

$2.8 billion

Industry Growth Rate

Poised to Grow at a CAGR of 10.5%

Market Driver

Advantages of primary human cells over cell lines

Market Opportunity

Advancing biomedical research using primary cells in 3D cultures

This report categorizes the primary cells market to forecast revenue and analyze trends in each of the following submarkets:

By Origin
  • Human Primary Cells
  • Animal Primary Cells
By Type
  • Hematopoietic Cells
  • Dermatocytes
  • Gastrointestinal Cells
  • Hepatocytes
    • Cryopreserved Hepatocytes
    • Fresh Hepatocytes
  • Lung Cells
  • Renal Cells
  • Heart Cells
  • Musculoskeletal Cells
  • Other Primary Cells
By End User
  • Pharmaceutical & Biotechnology Companies and CROs
  • Academic & Research Institutes
  • Other End Users
By Region
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments of Primary Cells Industry

  • In June 2023, iXCells Biotechnologies entered into an agreement with Tebubio to enhance the distribution of the company’s products throughout Europe.
  • In March 2022, Lonza launched human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, expanding

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 1 PRIMARY CELLS MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
           2.1.2 PRIMARY RESEARCH
                    FIGURE 2 PRIMARY CELLS INDUSTRY: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS (2022)
          FIGURE 5 ILLUSTRATIVE EXAMPLE OF MERCK KGAA: REVENUE SHARE ANALYSIS (2022)
          FIGURE 6 KEY INDUSTRY INSIGHTS
    2.3 GROWTH FORECAST 
          FIGURE 7 MARKET: CAGR PROJECTIONS, 2023–2028
          FIGURE 8 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 10 PRIMARY CELLS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 PRIMARY CELLS INDUSTRY, BY ORIGIN, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF PRIMARY CELLS MARKET
 
4 PREMIUM INSIGHTS (Page No. - 45)
    4.1 PRIMARY CELLS MARKET OVERVIEW 
          FIGURE 14 GROWING GLOBAL INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: PRIMARY CELLS INDUSTRY, BY END USER AND COUNTRY (2022) 
          FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS DOMINATED NORTH AMERICAN MARKET IN 2022
    4.3 MARKET SHARE, BY TYPE, 2023 VS. 2028 
          FIGURE 16 HEMATOPOIETIC CELLS SEGMENT TO DOMINATE MARKET IN 2028
    4.4 MARKET SHARE, BY ORIGIN, 2022 
          FIGURE 17 HUMAN PRIMARY CELLS SEGMENT DOMINATED MARKET IN 2022
    4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGH GROWTH RATES FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 48)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 PRIMARY CELLS INDUSTRY: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing cancer research
                                TABLE 5 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2020 VS. 2035
                                TABLE 6 ESTIMATED NUMBER OF NEW CASES OF ALL CANCERS (EXCLUDING NON-MELANOMA SKIN CANCER) FOR BOTH SEXES, 2020 VS. 2040
                    5.2.1.2 Advantages of primary human cells over cell lines
                    5.2.1.3 Increasing demand for monoclonal antibodies
                    5.2.1.4 Rapid growth in biotechnology and biopharmaceutical industries
                                FIGURE 20 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028
                    5.2.1.5 Growing focus on personalized medicine
                                TABLE 7 GROWTH IN NUMBER OF PERSONALIZED MEDICATIONS, 2015–2022
                    5.2.1.6 Government investments for cell-based research
           5.2.2 RESTRAINTS
                    5.2.2.1 Concerns regarding primary cell culture contamination
                    5.2.2.2 Ethical concerns regarding research in cell biology
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Advancing biomedical research using primary cells in 3D cultures
           5.2.4 CHALLENGES
                    5.2.4.1 Sourcing and availability of primary cells
    5.3 REGULATORY ANALYSIS 
           5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.4 PRICING ANALYSIS 
          TABLE 8 AVERAGE PRICE OF PRIMARY CELL PRODUCTS, BY KEY PLAYER (USD)
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 21 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 22 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 23 ECOSYSTEM ANALYSIS OF MARKET
          TABLE 9 MARKET ECOSYSTEM
    5.8 KEY CONFERENCES & EVENTS, 2023–2024 
          TABLE 10 MARKET: LIST OF CONFERENCES & EVENTS
    5.9 TECHNOLOGY ANALYSIS 
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 11 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF SUPPLIERS
           5.10.4 BARGAINING POWER OF BUYERS
           5.10.5 INTENSITY OF COMPETITIVE RIVALRY
    5.11 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRIMARY CELL PRODUCTS
           5.11.2 BUYING CRITERIA FOR PRIMARY CELLS
                     FIGURE 25 KEY BUYING CRITERIA FOR END USERS
 
6 PRIMARY CELLS MARKET, BY TYPE (Page No. - 68)
    6.1 INTRODUCTION 
          TABLE 12 PRIMARY CELLS INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    6.2 HEMATOPOIETIC CELLS 
           6.2.1 INCREASING CANCER RESEARCH & FUNDING TO PROPEL MARKET GROWTH
                    TABLE 13 TYPES OF HEMATOPOIETIC CELLS
                    TABLE 14 HEMATOPOIETIC CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 15 NORTH AMERICA: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 16 EUROPE: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 17 ASIA PACIFIC: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 DERMATOCYTES 
           6.3.1 RISING PREVALENCE OF MELANOMA TO BOOST DEMAND
                    TABLE 18 DERMATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 19 NORTH AMERICA: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 EUROPE: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 ASIA PACIFIC: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 GASTROINTESTINAL CELLS 
           6.4.1 GROWING INCIDENCE OF STOMACH CANCER TO BOLSTER GROWTH
                    TABLE 22 GASTROINTESTINAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 23 NORTH AMERICA: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 EUROPE: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 ASIA PACIFIC: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 HEPATOCYTES 
          TABLE 26 GLOBAL LIVER DISORDER INCIDENCE
          TABLE 27 HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 28 NORTH AMERICA: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 29 EUROPE: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 30 ASIA PACIFIC: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 31 HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
           6.5.1 CRYOPRESERVED HEPATOCYTES
                    6.5.1.1 Longer lifespan of cryopreserved hepatocytes than fresh hepatocytes to drive market growth
                                TABLE 32 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 33 NORTH AMERICA: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 34 EUROPE: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 35 ASIA PACIFIC CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.5.2 FRESH HEPATOCYTES
                    6.5.2.1 Stringent regulations and limited availability of fresh hepatocytes to limit market growth
                                TABLE 36 FRESH HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 37 NORTH AMERICA: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 38 EUROPE: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 39 ASIA PACIFIC: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.6 LUNG CELLS 
           6.6.1 INCREASING RATE OF LUNG CANCER & COPD TO DRIVE DEMAND FOR LUNG CELLS
                    TABLE 40 LUNG CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 41 NORTH AMERICA: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 42 EUROPE: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.7 RENAL CELLS 
           6.7.1 LACK OF AVAILABILITY OF EFFECTIVE RENAL THERAPIES TO PROPEL MARKET GROWTH
                    TABLE 44 RENAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 45 NORTH AMERICA: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 EUROPE: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.8 HEART CELLS 
           6.8.1 HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO SUPPORT GROWTH
                    TABLE 48 HEART CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 49 NORTH AMERICA: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 EUROPE: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.9 MUSCULOSKELETAL CELLS 
           6.9.1 RISING INCIDENCE OF MUSCULOSKELETAL DISORDERS TO PROPEL MARKET GROWTH
                    TABLE 52 MUSCULOSKELETAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 53 NORTH AMERICA: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 EUROPE: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 ASIA PACIFIC: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.10 OTHER PRIMARY CELLS 
           TABLE 56 OTHER MARKET, BY REGION, 2021–2028 (USD MILLION)
           TABLE 57 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           TABLE 58 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           TABLE 59 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 PRIMARY CELLS MARKET, BY ORIGIN (Page No. - 91)
    7.1 INTRODUCTION 
          TABLE 60 PRIMARY CELLS INDUSTRY, BY ORIGIN, 2021–2028 (USD MILLION)
    7.2 HUMAN PRIMARY CELLS 
           7.2.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
                    TABLE 61 HUMAN MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 ANIMAL PRIMARY CELLS 
           7.3.1 RISING INVESTMENTS IN ANIMAL CELL RESEARCH TO PROPEL MARKET GROWTH
                    TABLE 65 ANIMAL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 66 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 PRIMARY CELLS MARKET, BY END USER (Page No. - 97)
    8.1 INTRODUCTION 
          TABLE 69 PRIMARY CELLS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS 
           8.2.1 INCREASING INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH
                    TABLE 70 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 71 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 ACADEMIC & RESEARCH INSTITUTES 
           8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH AND HIGH PREVALENCE OF CANCER TO FAVOR MARKET GROWTH
                    TABLE 74 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 75 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 OTHER END USERS 
          TABLE 78 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 79 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 80 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 81 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 PRIMARY CELLS MARKET, BY REGION (Page No. - 104)
    9.1 INTRODUCTION 
          TABLE 82 PRIMARY CELLS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 26 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT
          TABLE 83 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 84 NORTH AMERICA: MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
          TABLE 85 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 86 NORTH AMERICA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 87 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 High R&D spending and growing support for stem cell research to drive market growth
                                TABLE 88 US: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 89 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 90 US: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 91 US: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Presence of advanced R&D infrastructure to boost market
                                TABLE 92 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 93 CANADA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 94 CANADA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 95 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.3 NORTH AMERICA: IMPACT OF RECESSION
    9.3 EUROPE 
          TABLE 96 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 97 EUROPE: MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
          TABLE 98 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 99 EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 100 EUROPE: PRIMARY CELLS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.3.1 UK
                    9.3.1.1 Growth in life science industry to fuel market growth
                                TABLE 101 UK: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 102 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 103 UK: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 104 UK: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.2 GERMANY
                    9.3.2.1 Increasing life science research activities to support market growth
                                TABLE 105 GERMANY: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 106 GERMANY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 107 GERMANY: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 108 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Robust biotechnology infrastructure to support growth
                                TABLE 109 FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 110 FRANCE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 111 FRANCE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 112 FRANCE: PRIMARY CELLS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Increasing number of cell biology seminars and conferences to fuel adoption of primary cells
                                TABLE 113 ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 114 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 115 ITALY: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 116 ITALY: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.5 REST OF EUROPE
                    TABLE 117 REST OF EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                    TABLE 118 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 119 REST OF EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 120 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.6 EUROPE: IMPACT OF RECESSION
    9.4 ASIA PACIFIC 
          FIGURE 27 ASIA PACIFIC: PRIMARY CELLS MARKET SNAPSHOT
          TABLE 121 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 122 ASIA PACIFIC: MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
          TABLE 123 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 124 ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 125 ASIA PACIFIC: PRIMARY CELLS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Growing focus on cancer therapeutics-related research to bolster growth
                                TABLE 126 CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 127 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 128 CHINA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 129 CHINA: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Government initiatives to propel market growth in Japan
                                TABLE 130 JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                                TABLE 131 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 132 JAPAN: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 133 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.3 REST OF ASIA PACIFIC
                    TABLE 134 REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
                    TABLE 135 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 136 REST OF ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 137 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.4 ASIA PACIFIC: IMPACT OF RECESSION
    9.5 REST OF THE WORLD 
          TABLE 138 REST OF THE WORLD: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
          TABLE 139 REST OF THE WORLD: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 140 REST OF THE WORLD: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 141 REST OF THE WORLD: PRIMARY CELLS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.5.1 REST OF THE WORLD: IMPACT OF RECESSION
 
10 COMPETITIVE LANDSCAPE (Page No. - 142)
     10.1 INTRODUCTION 
     10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
             FIGURE 28 PRIMARY CELLS MARKET: STRATEGIES ADOPTED
     10.3 REVENUE SHARE ANALYSIS 
             FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS (2019–2022)
     10.4 MARKET SHARE ANALYSIS 
             FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
             TABLE 142 PRIMARY CELLS INDUSTRY: DEGREE OF COMPETITION
     10.5 COMPANY EVALUATION QUADRANT 
             FIGURE 31 PRIMARY CELLS INDUSTRY: COMPANY EVALUATION MATRIX, 2022
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
     10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             10.6.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 143 PRIMARY CELLS INDUSTRY: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
             10.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 144 PRIMARY CELLS INDUSTRY: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
     10.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             FIGURE 32 PRIMARY CELLS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
             10.7.1 PROGRESSIVE COMPANIES
             10.7.2 STARTING BLOCKS
             10.7.3 RESPONSIVE COMPANIES
             10.7.4 DYNAMIC COMPANIES
     10.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 
             TABLE 145 PRIMARY CELLS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
             TABLE 146 PRIMARY CELLS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
     10.9 COMPETITIVE SCENARIO AND TRENDS 
             10.9.1 PRODUCT LAUNCHES
                        TABLE 147 MARKET: PRODUCT LAUNCHES, JANUARY 2020–JUNE 2023
             10.9.2 DEALS
                        TABLE 148 MARKET: DEALS, JANUARY 2020–JUNE 2023
             10.9.3 OTHER DEVELOPMENTS
                        TABLE 149 PRIMARY CELLS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JUNE 2023
 
11 COMPANY PROFILES (Page No. - 155)
     11.1 MAJOR PLAYERS 
(Business overview, Products offered, Recent Developments,  MNM view)*
             11.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
             11.1.2 MERCK KGAA
                        TABLE 151 MERCK KGAA: COMPANY OVERVIEW
                        FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 152 OTHER DEVELOPMENTS
             11.1.3 CORNING INCORPORATED
                        TABLE 153 CORNING INCORPORATED: BUSINESS OVERVIEW
                        FIGURE 35 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
             11.1.4 LONZA GROUP
                        TABLE 154 LONZA GROUP: BUSINESS OVERVIEW
                        FIGURE 36 LONZA GROUP: COMPANY SNAPSHOT (2022)
                        TABLE 155 PRODUCT LAUNCHES
             11.1.5 CHARLES RIVER LABORATORIES, INC.
                        TABLE 156 CHARLES RIVER LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 37 CHARLES RIVER LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 157 ACQUISITIONS
             11.1.6 PROMOCELL GMBH
                        TABLE 158 PROMOCELL GMBH: BUSINESS OVERVIEW
                        TABLE 159 PRODUCT LAUNCHES
             11.1.7 AMERICAN TYPE CULTURE COLLECTION (ATCC)
                        TABLE 160 AMERICAN TYPE CULTURE COLLECTION (ATCC): BUSINESS OVERVIEW
             11.1.8 CELL BIOLOGICS, INC.
                        TABLE 161 CELL BIOLOGICS, INC.: BUSINESS OVERVIEW
             11.1.9 ZENBIO, INC.
                        TABLE 162 ZENBIO, INC.: BUSINESS OVERVIEW
             11.1.10 STEMCELL TECHNOLOGIES, INC.
                        TABLE 163 STEMCELL TECHNOLOGIES, INC.: BUSINESS OVERVIEW
             11.1.11 ALLCELLS
                        TABLE 164 ALLCELLS: BUSINESS OVERVIEW
             11.1.12 IXCELLS BIOTECHNOLOGIES
                        TABLE 165 IXCELLS BIOTECHNOLOGIES: BUSINESS OVERVIEW
                        TABLE 166 AGREEMENTS
             11.1.13 NEUROMICS
                        TABLE 167 NEUROMICS: BUSINESS OVERVIEW
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
     11.2 OTHER COMPANIES 
             11.2.1 AXOL BIOSCIENCE LTD.
                        TABLE 168 AXOL BIOSCIENCE LTD.: COMPANY OVERVIEW
             11.2.2 STEMEXPRESS
                        TABLE 169 STEMEXPRESS: COMPANY OVERVIEW
             11.2.3 BIOIVT
                        TABLE 170 BIOIVT: COMPANY OVERVIEW
             11.2.4 SCIENCELL RESEARCH LABORATORIES, INC.
                        TABLE 171 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW
             11.2.5 AMSBIO
                        TABLE 172 AMSBIO: COMPANY OVERVIEW
             11.2.6 PROMAB BIOTECHNOLOGIES, INC.
                        TABLE 173 PROMAB BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
             11.2.7 CREATIVE BIOARRAY
                        TABLE 174 CREATIVE BIOARRAY: COMPANY OVERVIEW
             11.2.8 BPS BIOSCIENCE, INC.
                        TABLE 175 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW
             11.2.9 EPITHELIX
                        TABLE 176 EPITHELIX: COMPANY OVERVIEW
             11.2.10 REACHBIO RESEARCH LABS
                        TABLE 177 REACHBIO RESEARCH LABS: COMPANY OVERVIEW
             11.2.11 ACCEGEN
                        TABLE 178 ACCEGEN: COMPANY OVERVIEW
             11.2.12 KOSHEEKA
                        TABLE 179 KOSHEEKA: COMPANY OVERVIEW
 
12 APPENDIX (Page No. - 216)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global primary cells market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the Department of Health and Social Care (DHSC), the International Cell Line Authentication Committee (ICLAC), National Cancer Institute (NCI), Cancer Research UK, Israel Cancer Research Fund (ICRF), Breast Cancer Research Foundation (BCRF), Centre for Cellular & Molecular Biology (CCMB), European Collection of Authenticated Cell Cultures (ECACC), Chinese Academy of Medical Sciences (CAMS), National Centre for Cell Science (NCCS), GLOBOCAN, World Health Organization (WHO), National Center for Biotechnology Information (NCBI), US Food and Drug Administration (FDA). Secondary sources also include corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global primary cells market, which was validated through primary research.

Primary Research

Primary research was conducted to validate the market segmentation, identify key players, and gather insights into key industry trends and market dynamics.

Extensive primary research was conducted after acquiring basic knowledge about the global primary cells market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical & biopharmaceutical industries, academic & research institutes, and experts from the supply side, such as C-level & D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions: North America, Europe, Asia Pacific, and the Rest of the World. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Primary Cells Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The report presents a detailed assessment of the primary cells market and qualitative inputs and insights from MarketsandMarkets. The global size of the primary cells market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the primary cells and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the primary cells business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.   

Top- Down Approach

Primary Cells Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Bottom-up Approach

Primary Cells Market Size, and Share

Approach: MnM Repository Analysis

For this report, the previous version of the primary cells market were considered. The global and regional market values of the primary cells market and dependent submarkets were extracted from the MnM repository and validated through secondary and primary research. The final global market size was triangulated through the average of all approaches and validated through primary interviews with industry experts.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition:

Primary cells are the most physiologically and biologically relevant in vitro tools for biotechnology-based research. These cells are directly isolated from primary cell cultures of human or animal living tissue through enzymatic or mechanical methods. The integration of primary cells into cell-based research programs has helped to deliver biologically accurate and relevant data because they efficiently maintain their fundamental cellular functions.

Key Stakeholders

  • Research institutes
  • Manufacturers & distributors of primary cells
  • Clinical research organizations (CROs)
  • Academic research institutes
  • Biopharmaceutical & biotechnology companies
  • Cell banks
  • Venture capitalists and investors
  • Government associations dedicated to primary cells and cell culture preservation

Report Objectives

  • To define, describe, segment, and forecast the global primary cells market by origin, type, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches, expansions, and acquisitions in the primary cells market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the RoE primary cells market, by country
  • Further breakdown of the RoAPAC primary cells market, by country
  • Further breakdown of the RoW primary cells markets, by country

Company Information

  • Detailed analysis and profiling of additional market players (Up to five)

Segment Analysis

  • Further breakdown of the therapeutic area segment as per the product portfolio of prominent players operating in the market.  
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 6489
Published ON
Jul, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Primary Cells Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback